What are the most important things to look for when conducting a site initiation visit at a new research site?

A Site Initiation Visit (SIV) is the final readiness check before a research site begins enrolling participants. The main goal is to confirm that the site team, facilities, systems, and documentation are ready to conduct the study according to the protocol, Good Clinical Practice (GCP), and sponsor requirements.

Key areas to evaluate:

1. Regulatory and essential documents

Confirm that all required documents are complete, current, approved, and accessible:

• Current protocol and all amendments
• Current approved informed consent form (ICF) and recruitment materials
• IRB/IEC approval documentation
• Investigator’s Brochure (if applicable)
• Completed regulatory binder/site file
• Financial disclosure documentation (if required)
• CVs, licenses, and training records for investigators and delegated staff
• Delegation of Authority (DoA) log and signature records
• Required contracts and budgets completed

2. Investigator and site staff readiness

Assess whether the team understands their responsibilities:

• PI involvement and oversight expectations
• Roles and responsibilities of each team member
• Protocol-specific training completion
• GCP and human-subject protection training status
• Who can perform study procedures, obtain consent, enter data, and report safety events
• Backup coverage plans if key staff are unavailable

3. Protocol understanding

A major focus of the SIV is ensuring everyone understands how the study will be conducted:

• Study objectives and endpoints
• Inclusion/exclusion criteria
• Visit schedule and required assessments
• Randomization/blinding procedures (if applicable)
• Prohibited medications or procedures
• Protocol deviation prevention
• Participant withdrawal and discontinuation procedures

4. Informed consent process

Verify that the site has a compliant consent process:

• Only IRB/IEC-approved consent versions will be used
• Staff obtaining consent are trained and authorized
• Consent discussion requirements are understood
• Documentation requirements are clear
• Re-consent procedures are understood if amendments occur

5. Safety reporting and medical oversight

Confirm the team knows how to manage participant safety:

• Adverse event (AE) and serious adverse event (SAE) definitions
• Reporting timelines and pathways
• Pregnancy reporting (if applicable)
• Safety follow-up requirements
• PI review and oversight responsibilities

6. Investigational product/device readiness (if applicable)

For drug or device studies, verify:

• Receipt and storage requirements
• Temperature monitoring and excursion handling
• Drug/device accountability logs
• Dispensing procedures
• Return/destruction procedures
• Pharmacy or device team responsibilities

7. Laboratory and specimen processes

Review operational details:

• Required lab certifications
• Normal ranges (if applicable)
• Specimen collection procedures
• Processing, labeling, storage, and shipping requirements
• Availability of kits and supplies
• Courier/shipping procedures

8. Data management and study systems

Ensure the site can capture and maintain accurate data:

• Electronic Data Capture (EDC) access
• User accounts and permissions
• Case Report Form (CRF/eCRF) completion expectations
• Query resolution process
• Source documentation requirements
• Data entry timelines

9. Facilities and equipment

Tour the site and confirm:

• Adequate space for participant visits
• Privacy for consent and assessments
• Secure storage for records and study materials
• Required equipment availability and calibration
• Accessibility for participants
• Pharmacy, imaging, laboratory, or specialty areas if needed

10. Recruitment and enrollment readiness

Discuss:

• Recruitment strategy
• Expected enrollment targets
• Screening procedures
• Participant identification sources
• Screening/enrollment logs
• Potential recruitment barriers

11. Action items and activation requirements

Before leaving the SIV, make sure:

• All questions are answered or assigned for follow-up
• Deficiencies have owners and due dates
• Training gaps are closed
• Required documents are filed
• The site understands what must be completed before first patient enrollment

A useful way to judge SIV success is to ask: “If the site enrolled a participant tomorrow, would the team know exactly what to do, have the tools to do it, and be able to prove it was done correctly?” If the answer is yes, the site is generally ready for activation.

Conducting a Site Initiation Visit (SIV) is a critical milestone before a clinical research site can enroll participants. It ensures the site team understands the protocol, regulatory requirements, and operational expectations.

Here are the most important things to look for and verify during an SIV:

• Regulatory and Ethics Compliance : Verify that the final, approved version of the protocol, Investigator's Brochure (IB), and informed consent forms (ICFs) are on-site and match the Institutional Review Board (IRB) / Ethics Committee (EC) approval letters. Ensure all required regulatory documents (e.g., Form FDA 1572, financial disclosures) are fully executed and filed in the Investigator Site File (ISF).
• Investigator and Staff Qualifications : Confirm that the Principal Investigator (PI) and all sub-investigators/staff have current, valid licenses, up-to-date Curriculum Vitaes (CVs), and documented training on the protocol, Good Clinical Practice (GCP), and study-specific procedures.
• Delegation of Authority (DoA) : Review the Delegation of Authority log to ensure it accurately reflects trained personnel and that the PI has properly delegated study tasks. Check that no un-trained staff are performing trial-related duties.
• Investigational Product (IP) Management : Inspect the storage area for the investigational product. Verify that temperature monitoring systems (logging devices, calibrated thermometers) are in place, working, and set to the correct storage ranges (2∘C 2 raised to the composed with power C 2∘C to 8∘C 8 raised to the composed with power C 8∘C or controlled room temperature). Confirm that access to the IP storage is restricted and secure.
• Laboratory and Equipment Readiness : Inspect the lab and diagnostic equipment (centrifuges, freezers, ECG machines) to ensure they are calibrated, have valid maintenance logs, and that processing/storage capabilities match protocol specifications. Verify local lab reference ranges and certifications are filed.
• Source Documentation and Systems Access : Confirm the site has a clear plan for maintaining source documents and that electronic data capture (EDC) or eTMF systems access, logins, and vendor portals are active and functioning for the relevant team members.
• Informed Consent Process : Discuss and observe the site's operational workflow for obtaining and documenting informed consent. Ensure they have a secure process for storing signed ICFs and providing copies to participants.

If you'd like, I can help you with:

• Creating a printable SIV checklist template
• Specific compliance items for IP temperature excursion handling
• Guidance on preparing the Investigator Site File (ISF)

Let me know what aspect you'd like to explore further.

A Site Initiation Visit (SIV) is the final major readiness check before a research site begins enrolling participants. The goal is to confirm that the site has the people, training, documents, systems, and resources needed to conduct the study according to the protocol, Good Clinical Practice (GCP), regulations, and sponsor requirements.

The most important areas to evaluate are:

1. Study team readiness and responsibilities

• Confirm the Principal Investigator (PI) understands overall responsibilities and oversight expectations.
• Verify that all delegated staff are identified and appropriately qualified.
• Review the delegation of duties log and ensure staff know exactly what activities they may perform.
• Confirm completion of:
  • Protocol training
  • GCP training (as applicable)
  • System-specific training (EDC, randomization, ePRO, safety systems, etc.)
  • Laboratory or investigational product training, if applicable
• Assess whether staffing levels are adequate for recruitment and follow-up demands.

2. Protocol understanding

Ensure the team can explain:

• Study objectives and design
• Inclusion/exclusion criteria
• Visit schedule and required procedures
• Safety monitoring requirements
• Primary and secondary endpoints
• Prohibited medications or procedures
• Protocol deviation risks

A good SIV should not just confirm that staff received training—it should verify that they understand how to apply the protocol in practice.

3. Regulatory and essential documents

Review that the regulatory file/investigator site file is complete and organized, including:

• Current approved protocol and amendments
• Investigator brochure or device manual (if applicable)
• IRB/ethics approval documentation
• Approved informed consent forms
• Financial disclosure documents
• CVs and licenses for investigators and relevant staff
• Training records
• Laboratory certifications (if applicable)
• Required agreements and approvals

Missing or outdated documents are common causes of delays in site activation.

4. Informed consent process

Evaluate whether the site has a compliant consent process:

• Who obtains consent?
• Where is consent obtained?
• How are questions handled?
• How are consent versions controlled?
• How are re-consents managed after amendments?
• Where are signed forms stored?

The team should understand that no study procedures occur before valid informed consent is obtained.

5. Source documentation and data quality processes

Confirm:

• What constitutes source data for the study
• Where source records will be maintained
• How corrections will be made
• How confidentiality will be protected
• How electronic and paper records will be reconciled

Review expectations for:

• Case report forms (CRFs/eCRFs)
• Query management
• Data entry timelines
• Documentation of protocol-required assessments

6. Investigational product/device readiness (if applicable)

Check:

• Receipt and storage procedures
• Temperature monitoring
• Access controls
• Accountability logs
• Dispensing procedures
• Returns or destruction processes
• Emergency unblinding procedures (if applicable)

The site should be able to demonstrate that the investigational product can be managed safely from receipt through final accountability.

7. Laboratory and specimen handling

Verify:

• Required equipment is available and calibrated
• Lab reference ranges are available
• Staff understand collection procedures
• Specimen processing, labeling, storage, and shipping procedures are clear
• Required certifications are current

8. Safety reporting processes

Confirm the team understands:

• Adverse event (AE) documentation
• Serious adverse event (SAE) reporting timelines
• Pregnancy reporting (if applicable)
• Safety follow-up requirements
• Who is responsible for reviewing and reporting safety information

9. Recruitment and enrollment readiness

Assess:

• Recruitment strategy
• Patient population availability
• Referral pathways
• Screening procedures
• Screening/enrollment logs
• Advertising materials (if applicable)
• Realistic enrollment timelines

A site may be technically approved but still fail operationally if recruitment plans are unrealistic.

10. Systems and operational readiness

Confirm access and readiness for:

• EDC system
• Randomization/IRT system
• Electronic trial master file or document systems
• Safety reporting systems
• Patient-reported outcome systems
• Imaging or specialty platforms (if applicable)

11. Facility assessment

Tour relevant areas:

• Participant visit rooms
• Secure record storage
• Pharmacy (if applicable)
• Laboratory areas
• Equipment storage
• Monitoring space

Confirm facilities support privacy, safety, and protocol requirements.

12. Identify and document action items

Before closing the visit:

• Summarize findings with the PI and site team
• Assign owners and due dates for open items
• Determine whether the site is ready for activation
• Document training completed and outstanding requirements

A successful SIV results in confidence that the site can enroll the first participant while maintaining compliance and data integrity.

A practical way to prioritize during the visit is:

1. Can the site safely enroll and treat participants?
2. Can the site collect reliable, protocol-compliant data?
3. Can the site demonstrate compliance through documentation?
4. Are there any barriers that could delay activation or recruitment?

A Site Initiation Visit (SIV) is the final gatekeeper before a clinical trial site can be activated to enroll participants. It ensures that the research team is not only theoretically familiar with the protocol, but operationally ready to protect human subjects and collect audit-ready data.

When conducting an SIV, focus on these critical areas of readiness:

1. Regulatory and Essential Documentation (ISF)
   • Verify that the Investigator Site File (ISF) is established, structured, and complete.
   • Check that final, approved IRB/Ethics Committee approvals, the current protocol, signed financial disclosures, and the Investigator’s Brochure are properly filed.
2. Delegation of Authority (DoA) and Training Logs
   • Review the Delegation of Authority Log to ensure every team member’s specific study roles are clearly assigned by the Principal Investigator (PI) and initialed/signed.
   • Confirm that protocol-specific and Good Clinical Practice (GCP) training records are documented for all attending staff.
3. Investigational Product (IP) and Pharmacy Readiness
   • Inspect the physical drug storage area (pharmacy or secure clinic space) for appropriate security, restricted access, and environmental controls.
   • Review temperature monitoring systems, logs, accountability forms, and dispensing/destruction workflows.
4. Facility and Equipment Compliance
   • Conduct a physical or virtual walkthrough of the clinic, lab processing spaces, and private consent rooms.
   • Check calibration and maintenance logs for all study-critical equipment (e.g., centrifuges, -80∘C negative 80 raised to the composed with power C−8 0∘C freezers, ECG machines, or specialized diagnostic tools).
5. Technology and System Access
   • Confirm that the PI and study coordinators have active, working credentials for all digital platforms, such as the Electronic Data Capture (EDC) system, Interactive Response Technology (IWRS/IXRS), and safety reporting portals.
6. Protocol and Safety Procedures Alignment
   • Walk through the inclusion/exclusion criteria, visit schedules, and participant retention/withdrawal procedures with the staff.
   • Clarify expectations for defining source documents and reporting adverse events (AEs) and serious adverse events (SAEs).

Are you preparing for an SIV from the perspective of a Sponsor/CRA monitor or as a site coordinator/investigator ? Let me know, and I can tailor a specific walkthrough checklist for your role.

A good Site Initiation Visit (SIV) should answer one fundamental question:

“Is this site genuinely ready to enroll the first participant safely, compliantly, and according to the protocol?”

The most important areas I would assess are:

1. Investigator engagement and oversight

• Is the PI actively engaged, knowledgeable about the protocol, and available to oversee the study?
• Does the PI understand their regulatory responsibilities and delegation obligations?
• Are the PI and key staff clear on who is responsible for what?
• Does the delegation of duties make sense for the site's actual workflow?

This is more important than simply confirming that people attended training. You want evidence that the PI and team understand how the study will actually operate.

2. Regulatory and essential documents

Confirm that the site has the required, current, approved documentation, including:

• Protocol and amendments
• Investigator's Brochure, if applicable
• IRB/IEC approval
• Current informed consent documents and approved recruitment materials
• CVs/licensure/training documentation
• Delegation of authority log
• Financial disclosures, as applicable
• Regulatory/essential document file
• Applicable laboratory certifications and normal ranges

ICH GCP emphasizes that essential records should allow evaluation of both trial conduct and reliability of the results.

3. Protocol understanding — especially the high-risk parts

Don't just ask, “Has everyone read the protocol?”

Walk through the procedures that are most likely to generate errors:

• Eligibility criteria
• Screening procedures
• Randomization/blinding
• Primary endpoint assessments
• Visit windows
• Prohibited/concomitant medications
• Safety assessments
• AE/SAE identification and reporting
• Protocol deviation handling
• Withdrawal criteria
• Pregnancy reporting, if applicable
• Specimen collection/processing/shipping

A particularly useful technique is to ask the coordinator or investigator to talk you through a hypothetical first participant from screening through enrollment. This exposes workflow gaps much faster than a slide presentation.

4. Informed consent process

This deserves special attention.

Determine:

• Where and when consent will occur
• Who is authorized to obtain consent
• How the correct IRB-approved version will be controlled
• How consent discussions will be documented
• How participants receive a copy
• How re-consent will be handled after amendments
• How electronic consent works, if applicable

The key principle is that consent must occur before participation in trial procedures, consistent with GCP and the approved protocol.

5. Facilities, equipment, and patient flow

Physically walk through the site.

Look at:

• Exam/treatment rooms
• Privacy and confidentiality
• Emergency equipment
• Laboratory/phlebotomy areas
• Processing and centrifugation areas
• Specimen storage
• Investigational product storage
• Temperature monitoring
• Equipment calibration/maintenance
• Secure document storage
• Participant flow through the facility

A site can look excellent on paper but have a completely impractical workflow.

6. Investigational product and study supplies

If the trial involves an investigational product, verify the entire chain of custody:

• Receipt
• Storage requirements
• Temperature monitoring
• Access control
• Accountability
• Dispensing
• Administration
• Returns/destruction
• Emergency unblinding, if applicable

Also confirm that the site actually has the supplies needed to perform the study—not merely that they have been ordered. ICH GCP specifically identifies appropriate storage, accountability, dispensing, and disposition of investigational product as monitoring considerations.

7. Laboratory and specimen logistics

This is a frequent source of avoidable deviations.

Confirm:

• Which laboratory performs each test
• Certifications/accreditations where applicable
• Reference ranges
• Sample collection requirements
• Processing requirements
• Centrifuge/freezer availability
• Storage temperatures
• Shipment schedules
• Courier arrangements
• Backup plans for equipment failure or missed shipments

For complex studies, I would actually walk through a sample from collection → processing → labeling → storage → shipment.

8. Data systems and source documentation

Make sure the site's data infrastructure is ready:

• EDC access
• Randomization/IRT access
• ePRO/eCOA systems
• Safety systems
• Central laboratory portals
• User accounts and role-based access
• Source documentation templates
• Medical-record access
• Data privacy/security procedures
• Backup procedures

Also ask: “Where will the source data for each primary endpoint actually live?”

That question can uncover major problems early.

9. Safety reporting and medical escalation

The team should know exactly:

• Who evaluates AEs
• Who determines seriousness/expectedness/causality
• How SAEs are reported
• Reporting timelines
• Who is available after hours
• What happens when the PI is unavailable
• How urgent safety information reaches participants and investigators

You want to see a realistic escalation pathway, not just a phone number in the regulatory binder.

10. Recruitment feasibility

Assess whether the site can actually deliver its enrollment commitment.

Ask about:

• Available patient population
• Competing studies
• Referral sources
• Recruitment strategy
• Screening volume
• Expected screen-failure rate
• Staffing capacity
• Historical enrollment in similar studies

Be skeptical of enrollment projections that aren't supported by actual patient-flow data.

11. Training and competency

Confirm training for all staff performing delegated study activities, not just attendance at the SIV.

Look for:

• Protocol training
• GCP training
• Safety training
• EDC/IRT training
• Lab/specimen training
• IP training
• Informed-consent training
• Equipment-specific training

NCCIH guidance similarly emphasizes confirming that staff understand their roles and that the necessary documents, systems, supplies, and facilities are ready before implementation.

12. Identify the “failure points” before enrollment

This is arguably the most valuable part of the SIV.

Ask the team:

“What could cause your first participant to be enrolled incorrectly?”

Then:

“What could cause a serious protocol deviation?”

And:

“What could go wrong with the primary endpoint?”

Those questions tend to reveal weaknesses in workflow, staffing, eligibility interpretation, consent, specimen handling, or data collection that a conventional checklist misses.

---

My top 5 priorities

If I had limited time, I'd prioritize:

1. PI oversight and staff competency
2. Participant safety and informed consent
3. Protocol/eligibility/endpoint understanding
4. Operational readiness of facilities, IP, labs, and systems
5. Source data and documentation/data integrity

The underlying GCP objectives are protection of participants, reliable/verifiable data, and compliance with the protocol and applicable requirements.

One important distinction

An SIV shouldn't be treated as “training day + paperwork review.” It is really a readiness assessment. NCCIH, for example, expects the site to demonstrate that the necessary documents, SOPs/QC processes, CRFs, database, supplies, and facilities are ready, with action items resolved or appropriately addressed before enrollment.

A strong SIV therefore ends with clear action items, owners, deadlines, and an explicit decision about whether the site is ready to enroll.

Conducting a Site Initiation Visit (SIV) is a critical milestone before a clinical research site can enroll patients. It bridges the gap between site selection and active recruitment.

Here are the most important things to verify and evaluate during an SIV, organized by category:

• Regulatory and Governance Compliance , ensuring all essential documents—like the final IRB/IEC-approved protocol, informed consent form (ICF), signed FDA Form 1572 (or local equivalent), and financial disclosure forms—are fully signed, dated, and filed in the Investigator Site File (ISF) before any trial procedures begin.
• Protocol and Procedural Training , confirming that the Principal Investigator (PI) and all delegated study staff are thoroughly trained on the protocol, endpoint definitions, safety reporting timelines, and any protocol-specific nuances.
• Investigational Product (IP) Management , inspecting the storage area to verify that temperature logs, security measures (restricted access/lock), and accountability procedures for I P cap I cap P𝐼𝑃 (and emergency unblinding kits, if applicable) meet protocol and Good Clinical Practice (GCP) requirements.
• Laboratory and Equipment Calibration , reviewing current calibration and maintenance records for all equipment used in the study (e.g., centrifuges, -80∘C negative 80 raised to the composed with power cap C−8 0∘𝐶 freezers, ECG machines, thermometers) and ensuring central/local lab accreditations and normal ranges are up to date.
• Data and Source Document Workflow , verifying the setup of the Electronic Data Capture (EDC) system, source document generation plans, and procedures for maintaining ALCOA+ data integrity principles (Attributable, Legible, Contemporaneous, Original, Accurate).
• Safety and Emergency Procedures , checking that the team knows the exact workflow for managing, documenting, and reporting Serious Adverse Events (SAEs) within the required windows (e.g., within 24 24 2 4 hours), and confirming local medical emergency response plans are in place.
• Delegation of Authority (DoA) , auditing the site staff's Delegation Log to ensure everyone listed has the appropriate training, qualifications, CVs, and medical licensure to perform their assigned study tasks.

If you'd like, I can:

• Provide a step-by-step SIV checklist template
• Detail the PI's specific responsibilities during the visit
• Focus on remote vs. on-site SIV best practices

Let me know how you want to proceed or tailor this.

Conducting a Site Initiation Visit (SIV) is a critical milestone before a clinical research site can enroll any participants. It ensures the site is operationally ready, compliant with Good Clinical Practice (GCP), and fully understands the protocol.

Here are the most important areas to focus on during an SIV:

• Regulatory and Ethics Compliance: Verify that all essential documents—such as the final IRB/IEC-approved protocol, informed consent forms (ICFs), Investigator's Brochure (IB), and regulatory approvals (like FDA Form 1572 or local equivalent)—are fully executed, signed, and filed in the Investigator Site File (ISF) or Trial Master File (TMF).
• Protocol and Study Procedures Training: Confirm that the Principal Investigator (PI) and all delegated research staff have received comprehensive training on the protocol, endpoint definitions, schedule of assessments, and specific study workflows.
• Investigational Product (IP) Management: Inspect the storage facilities to ensure secure, temperature-controlled, and monitored environments (with calibrated logs) for the IP, along with verifying clear accountability, receipt, and dispensing procedures.
• Laboratory and Equipment Readiness: Check that all laboratory equipment (centrifuges, freezers, scales) required for the trial has current calibration and maintenance records, and review the central/local lab processing and sample shipping instructions.
• Source Documentation and Data Flow: Ensure the site understands the source documentation plan, how corrections will be made, and the use of Electronic Data Capture (EDC) systems or Clinical Trial Management Systems (CTMS), including user access and delegation logs.
• Safety Reporting and Emergency Procedures: Review the procedures and timelines for reporting Serious Adverse Events (SAEs) to the sponsor/IRB, and confirm that the site has a clear plan for managing medical emergencies and unblinding if applicable.
• Subject Recruitment and Retention Plan: Discuss the site’s concrete recruitment strategy, screening pipeline, and confirm their understanding of the proper consenting process (ensuring subjects sign the current IRB-approved ICF version before any study-related procedures).
• Delegation of Authority (DoA) Log: Ensure the DoA log is accurate, up-to-date, and signed by the PI, clearly outlining the qualified staff assigned to specific protocol tasks.

If you'd like, I can:

• Provide a downloadable or printable checklist for the visit
• Detail how to handle deviations or missing items found on-site
• Focus on remote vs. on-site SIV differences

Let me know how you want to proceed.

For a site initiation visit (SIV), the main question is: “Is this site genuinely ready to enroll the first participant safely, compliantly, and according to the protocol?” ICH GCP emphasizes adequate investigator qualifications, resources, facilities, training, essential records, and appropriate investigational-product management.

I’d focus on these areas, roughly in this order:

1. Investigator and site readiness

• Is the PI engaged, available, and clearly accountable for the study?
• Are all sub-investigators and key staff appropriately qualified?
• Is there enough staffing capacity for the expected recruitment and visit schedule?
• Are roles and responsibilities clearly delegated?
• Does the team understand who does what, when, and what requires PI oversight?
• Are there any competing studies or workload issues that could affect recruitment or follow-up?

ICH specifically calls for confirmation that investigators and involved staff have appropriate qualifications, resources, facilities, and equipment.

2. Protocol understanding — don't just ask whether they've read it

This is one of the most important parts of the SIV.

Walk the team through the actual patient journey:

1. Referral/pre-screening
2. Eligibility assessment
3. Informed consent
4. Baseline procedures
5. Randomization
6. Investigational product/device administration
7. Safety assessments
8. Laboratory/sample handling
9. Follow-up
10. AE/SAE reporting

Look particularly for areas where the protocol is complicated or where an error could affect participant safety or a primary endpoint.

Ask scenario-based questions such as:

“A patient meets all criteria except X. What do you do?”

“The patient arrives for Visit 3 but the required lab isn't available. What's your process?”

That often reveals much more than asking, “Does everyone understand the protocol?”

3. Informed consent process

Confirm that the site has a realistic, compliant consent process, not simply a signed consent form.

Look at:

• Where consent will occur
• Who is authorized to obtain it
• How much time participants will have to consider participation
• How questions are handled
• How consent discussions are documented
• How amended consent forms will be managed
• What happens if a participant cannot consent independently

The consent process should occur before study procedures requiring consent, and the site should be able to demonstrate that process.

4. Investigational product/device readiness

If there is an IP or investigational device, this deserves a detailed walkthrough.

Check:

• Receipt and shipment procedures
• Storage requirements and temperature monitoring
• Restricted access
• Accountability/reconciliation
• Dispensing/administration procedures
• Dose preparation, if applicable
• Returns/destruction
• Emergency/unblinding procedures
• Drug/device accountability records
• Staff training
• Backup arrangements for excursions or equipment failures

ICH specifically identifies appropriate storage, handling, accountability, dispensing, and disposition as important areas of oversight.

5. Facilities and equipment

Physically walk the site. Don't rely solely on a questionnaire.

Verify that the actual environment supports the protocol:

• Exam/treatment rooms
• Emergency equipment
• Pharmacy/IP storage
• Laboratory
• Centrifuge/freezer, if applicable
• Temperature monitoring
• Sample processing/storage
• Specimen shipping area
• Equipment calibration/maintenance
• Secure records/storage areas
• Participant privacy

A good test is: “Show me where this happens.”

If they say samples are processed within 30 minutes, ask them to show you the equipment, workspace, SOP, and workflow that makes that possible.

6. Laboratory and specimen management

This is frequently underestimated.

Understand the complete chain:

Collection → labeling → processing → storage → shipment → receipt

Check:

• Required lab certifications/qualifications
• Normal/reference ranges where applicable
• Processing requirements
• Timing windows
• Storage temperatures
• Freezer backup
• Shipment schedules
• Courier arrangements
• Holidays/weekends
• Sample reconciliation
• Handling of deviations or damaged/missing samples

ICH R3 also emphasizes that laboratory activities and other tests should be fit for purpose.

7. Safety and AE/SAE reporting

Make sure everyone knows:

• What constitutes an AE/SAE
• Who assesses causality/severity
• Who must be notified
• Reporting timelines
• Where the information is documented
• What happens after hours
• Who covers when the PI is unavailable
• How protocol-specific safety events are handled

Don't just train the coordinator—make sure the clinical team that will actually recognize and manage safety events understands the requirements.

8. Source data and data flow

You want a clear answer to:

“Where does every critical piece of study data originate?”

Map: Source → EHR/source system → CRF/eCRF → query → correction → final data

Clarify:

• What constitutes source data
• Where source records are maintained
• Who can enter data
• How corrections are made
• How EHR data will be accessed
• PI oversight/sign-off requirements
• Handling of outside records
• Data privacy/security
• Access to electronic systems

ICH and FDA emphasize maintaining essential records and being able to identify where source and other essential information resides.

9. Recruitment feasibility

Don't accept “We can recruit 10 patients/month” without evidence.

Ask:

• How many potentially eligible patients does the site actually see?
• How are they identified?
• Who performs pre-screening?
• What are the likely exclusion criteria?
• Are there competing trials?
• How long does IRB/contracting typically take?
• What recruitment methods are planned?
• What is the realistic first-patient-in date?

I'd distinguish between theoretical patient population and patients the site can realistically recruit.

10. Essential documents and regulatory readiness

Before activation, make sure the required documentation is in place or has a clearly defined path to completion.

This may include:

• IRB/IEC approval
• Current protocol
• Investigator's Brochure/device information
• CVs and qualifications
• Training records
• Delegation of authority
• Financial disclosures
• Laboratory documentation
• Regulatory approvals
• Contracts/budget
• Essential document filing system

Essential documents should allow evaluation of trial conduct and data quality and should be maintained in a way that supports retrieval and inspection.

11. Systems and technology

Verify that staff can actually use the required systems:

• EDC
• ePRO/eCOA
• IRT/IWRS
• eTMF/site document system
• Safety reporting system
• Randomization system
• Central laboratory portal
• Imaging systems, if applicable

Check that accounts are provisioned before activation, rather than discovering after activation that the coordinator can't log in.

12. Contingency planning

This is an excellent indicator of site maturity.

Ask:

• What happens if the PI is unavailable?
• What happens if the freezer fails?
• What happens during a power outage?
• What happens if the EHR is down?
• What happens if the IP temperature excursion occurs?
• Who handles an SAE after hours?
• Who covers the coordinator during leave?
• What happens if a shipment is delayed?

A site that has thought through these scenarios is usually much safer than one that simply says, “We'll figure it out.”

---

The five things I'd be most concerned about

If time is limited, I'd prioritize:

A useful overarching principle is risk-based focus: spend the most SIV time on processes where failure could affect participant safety, critical endpoints, or data integrity, rather than treating every protocol requirement as equally important. FDA's monitoring guidance similarly recommends focusing oversight on the most important aspects of study conduct and reporting.

One practical SIV technique

For each critical study activity, ask the site to show you the workflow rather than describe it:

“Show me how you would do this with your first patient tomorrow.”

Then walk through the actual room, system, source document, equipment, staff member, and documentation involved.

That tends to uncover readiness gaps—missing equipment, unclear delegation, unrealistic timelines, inadequate source documentation, system-access problems, or misunderstandings of the protocol—that a conventional slide-based SIV can easily miss.

For a Site Initiation Visit (SIV), I’d focus less on simply “covering the slides” and more on answering one question:

Is this site genuinely ready to enroll its first participant, and does everyone understand how to conduct the study correctly and safely?

The most important areas are:

1. Investigator and site readiness

• Is the PI engaged, available, and knowledgeable about the protocol?
• Are delegated staff appropriately qualified and trained?
• Is there a clear delegation-of-responsibility structure?
• Does the PI understand their continuing oversight responsibilities?
• Are there adequate staffing levels for the expected enrollment and visit burden?

The investigator remains responsible for conducting the study according to the protocol and applicable requirements and for protecting participant safety and welfare.

2. Protocol understanding

This is probably the most important SIV discussion.

Make sure the team understands:

• Inclusion/exclusion criteria
• Primary and secondary endpoints
• Visit schedule and windows
• Required procedures and assessments
• Concomitant medication restrictions
• Randomization/blinding requirements
• Protocol deviations and how to prevent/report them
• Withdrawal/discontinuation criteria
• Special safety considerations

Don't just ask whether they've read the protocol. Use scenario-based questions, such as: “A patient meets all criteria except X—what do you do?”

3. Patient recruitment and enrollment feasibility

Reality-check the site's enrollment assumptions:

• Where will participants come from?
• How many potentially eligible patients does the site actually see?
• Who identifies and pre-screens them?
• How will referrals work?
• How quickly can screening occur?
• Are there competing studies?
• Does the site have enough time and staff to recruit at the expected rate?

A site that looks excellent operationally but cannot recruit appropriate participants is still a high-risk site.

4. Safety and medical oversight

Confirm that everyone knows:

• How AEs/SAEs are identified and documented
• Reporting timelines
• Who evaluates safety events
• Who is available after hours
• Emergency/unblinding procedures, if applicable
• Pregnancy reporting, if relevant
• Required safety laboratory/imaging assessments
• How urgent safety information reaches the PI and sponsor

The FDA specifically emphasizes investigator responsibility for participant safety and appropriate reporting/oversight.

5. Investigational product/device management

For drug studies, walk through the actual flow, not just the theory:

• Receipt and accountability
• Storage conditions and temperature monitoring
• Access/security
• Dispensing and administration
• Dose modifications
• Returns/destruction
• Emergency access/unblinding, if applicable

The investigator is responsible for appropriate control of investigational drugs and maintaining adequate accountability records.

For device studies, similarly verify storage, inventory, calibration, device accountability, maintenance, and handling of malfunction/device deficiencies.

6. Source documentation and data flow

This is an area I would scrutinize carefully.

Understand: Participant → source record → CRF/EDC → query → data review

Check:

• Where will each critical data point originate?
• Are source documents clearly identifiable?
• Who enters data?
• How quickly will data be entered?
• How are corrections made?
• How are external/vendor data reconciled?
• Who reviews/signs off?
• Can the site reconstruct what happened to a participant?

ICH GCP E6(R3) emphasizes essential records as evidence of appropriate trial conduct, investigator/sponsor oversight, and reliability of results.

7. Regulatory and essential documents

Before activation, verify that required documentation is complete and current, including as applicable:

• IRB/IEC approval
• Protocol and amendments
• Investigator Brochure/device information
• Informed consent documents
• CVs and qualifications
• GCP/training documentation
• Financial disclosures
• Delegation logs
• Laboratory certifications/normal ranges
• Licenses and accreditations
• Required contracts and regulatory documents

Also make sure the correct versions are being used. A site having a document isn't enough—the document needs to be current, applicable, and appropriately filed.

8. Informed consent process

Don't treat consent as just another training topic.

Ask the site to explain:

• Who will obtain consent?
• Where will it occur?
• How much time will participants have?
• How will comprehension be assessed?
• What happens if the participant has questions?
• What happens if new safety information becomes available?
• How will re-consent be handled?

The consent process must occur appropriately before study procedures requiring consent, subject to applicable exceptions.

9. Facilities, equipment, and vendors

Physically verify that the site can actually perform the protocol.

Look at:

• Exam/treatment rooms
• Pharmacy/storage areas
• Temperature-controlled storage
• Laboratory capabilities
• Centrifuges/freezers, if required
• Imaging capabilities
• Emergency equipment
• Sample processing/shipping areas
• Equipment calibration/maintenance
• Backup systems

If the study relies on central labs, imaging vendors, couriers, ePRO/eCOA, IRT/IWRS, etc., make sure the site's workflow with each vendor is understood.

10. Training and communication

By the end of the SIV, each relevant team member should know:

• What they are responsible for
• How they perform it
• When they perform it
• What documentation is required
• Who they contact when something goes wrong

Pay particular attention to staff who weren't in the room for the SIV. Establish how future/new staff will be trained and documented.

11. Study-specific risks and failure points

This is where an experienced CRA/monitor can add a lot of value.

Ask:

“Where is this study most likely to go wrong at this particular site?”

Examples:

• Difficult eligibility criterion
• Complex dosing
• Narrow visit windows
• Intensive PK sampling
• Specialized imaging
• Frequent patient-reported outcomes
• Complicated randomization
• Limited pharmacy coverage
• High staff turnover
• Recruitment dependence on referrals

Then agree on preventive actions before the first participant.

12. Activation criteria and next steps

Don't leave the SIV with vague statements like “the site looks good.”

Create a clear activation/action-item list:

The ultimate goal is a documented determination that the site is ready—not simply that the SIV occurred.

My “top 5” if time is limited

If you only have time to deeply evaluate five things, I'd prioritize:

1. PI/staff understanding and oversight
2. Protocol and eligibility understanding
3. Participant safety and SAE processes
4. Source/data integrity and documentation
5. Actual recruitment and operational feasibility

And one practical tip: walk the process as if the first participant arrives tomorrow. Start with “patient identified,” then walk through screening → consent → baseline → randomization → treatment → safety event → data entry → follow-up. You'll uncover gaps much faster than by reviewing a checklist item-by-item.

For U.S. drug trials, these considerations should be aligned with the applicable FDA requirements; for multinational studies, also anchor the SIV to the current ICH GCP E6(R3) framework and local requirements.

Conducting a Site Initiation Visit (SIV) is the final checkpoint before a clinical trial site can be officially activated to enroll participants. It acts as a bridge between startup preparation and active study conduct.

The most important areas to evaluate and verify during an SIV include:

• Regulatory and Essential Document Completeness
  Verify that the Investigator Site File (ISF) or regulatory binder is fully established. Look for current Institutional Review Board/Ethics Committee (IRB/EC) approvals, the final signed protocol, the Investigator’s Brochure, signed financial disclosure forms, and fully executed clinical trial agreements. Crucially, verify that the FDA Form 1572 (or regional equivalent) is accurate and signed.
• Delegation of Authority (DoA) Log and Training Records
  Ensure that all participating site staff (Principal Investigator, sub-investigators, coordinators, pharmacists, and lab techs) have completed mandatory study-specific, protocol, and Good Clinical Practice (GCP) training. Cross-reference this against the Delegation of Authority log to confirm that roles are assigned only to qualified, trained personnel.
• Investigational Product (IP) and Pharmacy Readiness
  Inspect the storage facilities (such as investigational pharmacies or secure clinical refrigerators/freezers) to ensure physical readiness. Confirm that temperature-monitoring devices are calibrated and functioning, accountability logs are ready, and staff understand the precise processes for receiving, storing, dispensing, returning, or destroying the IP.
• Protocol Comprehension and Patient Recruitment Strategy
  Assess the site team’s operational grasp of the protocol—specifically the inclusion/exclusion criteria, visit schedules, randomization workflows, and screening procedures. Review their practical plan for identifying, recruiting, and retaining eligible participants.
• Safety Reporting and Data Management Workflows
  Confirm that the team knows how to identify and report Adverse Events (AEs) and Serious Adverse Events (SAEs), including strict reporting timelines (e.g., 24-hour notifications). Test or verify active, secure user access to the Electronic Data Capture (EDC) system, interactive response technology (IWRS), and any other digital platforms required for the trial.
• Facility, Equipment, and Lab Infrastructure Walkthrough
  Tour the physical clinical spaces, processing laboratories, and emergency equipment areas. Ensure that lab processing kits, centrifuge equipment, and biological sample storage are present, labeled correctly, and adequate for protocol requirements.

If you are preparing for an upcoming SIV, would you like to focus on creating a customized on-site agenda or drafting a post-visit follow-up/action item tracker?